Kornimate/medical-research-clean huggingface dataset:
correlates of gerd symptom severity

Conditions: GERD

Summary: this is a pilot study measuring physiologic and behavioral correlates of symptom severity in adult patients with gastroesophageal reflux disease (gerd).

subjects will complete questionnaires regarding their gerd-related symptoms and have a visit with a study clinician regarding their symptoms. we will measure heart rate variability and galvanic skin response in patients during the visits and video record the visits. subjects will complete a daily gerd symptom diary for 2 weeks and then return to the study center to complete additional questionnaires and an exit interview.

Eligibility criteria:
inclusion criteria: * adults ages 21-70 years old * heartburn symptoms 3 or more days per week with an average daily symptom severity of 3 or more on a 7 day baseline symptom diary * english language proficiency * willingness to be videotaped and connected to physiologic monitoring devices during the visit exclusion criteria: * diagnosis of crohn's disease, systemic sclerosis, known active ulcer disease, gastric cancer, or untreated/active barrett's esophagitis based on subject self-report and/or medical record review * heavy alcohol use (\> 6 drinks/week for women and \> 13 drinks/week for men) * pregnant women. * dementia or significant memory difficulties * severe, unstable psychiatric disease * greater than 15 doses of nonsteroidal anti-inflammatory drugs (nsaids) within the prior 30 days (aspirin ≤ 325 mg daily permitted) or ongoing nsaid use at a level deemed likely to interfere with the study * failure to complete the baseline symptom diary for at least 6 of 7 days * change in gerd treatment regimen within the last 2 weeks (subjects may use antacids, h2 receptor blockers, and/or proton pump inhibitors as long as they are symptomatic on a stable regimen) * allergy to adhesives * inability to provide informed consent

Keywords: gerd galvanic skin response heart rate variability
influence of obesity on endogenous oxalate synthesis

Conditions: Kidney Stone

Summary: there is increasing evidence that obesity is associated with increased urinary oxalate excretion, an important risk factor for calcium oxalate stone formation. by the administration of a controlled low oxalate diet the investigators will estimate endogenous oxalate synthesis in both non-obese and obese non-kidney-stone forming adults. this study seeks to thusly increase the understanding of the relationships between obesity and endogenous oxalate synthesis to serve as a platform to develop novel therapies for stone prevention.

calcium oxalate stone disease results in billions of dollars in healthcare costs per year, creates large economic losses due to decreased work productivity, and produces significant pain and suffering in affected individuals impacting quality of life. almost 9% of the population in the united states may now experience a stone event at least once in their lifetime and that figure is increasing. although stone removing treatments have advanced in the last few decades with a variety of minimally invasive procedures such as shock wave lithotripsy, ureteroscopy and percutaneous nephrolithotomy, our knowledge of how stones form and how to prevent them has not kept pace. approximately 70-80% of the stones formed contain oxalate. oxalate is an end product of metabolism and an ubiquitous element of human diets. small increases in urinary oxalate can increase calcium oxalate crystal formation and thus stone disease. urinary oxalate levels are affected by both dietary and endogenous components, complicating the discrimination between the two sources. multiple epidemiological and clinical studies have demonstrated a link between body mass index (bmi) and kidney stone disease and also an increased urinary oxalate excretion. the interpretation of studies suggesting a link between obesity and the amount of urinary oxalate excreted is confounded by the failure in most studies to use diets controlled in calcium and oxalate. adult humans without a history of kidney stones will be placed on controlled low oxalate diets to estimate the contribution of endogenous oxalate synthesis to the urinary oxalate pool. in addition, oral doses of 13c2-glycolate and 13c6- vitamin c will be used to determine their conversions to 13c2-oxalate and provide an index of endogenous oxalate production. body morphometric indices, markers of oxidative stress, and insulin resistance will be assessed in these subjects.they will also be evaluated with dxa and mri to define body fat content and distribution.

Eligibility criteria:
inclusion criteria: * age 25-60 years * body mass index (bmi) \<50 exclusion criteria: * history of kidney stones * history of diabetes, hepatic disease, renal disease including chronic kidney disease (ckd), bowel disease or other endocrine disorders * pregnant or lactating women, or those with the intention to become pregnant in the near future * abnormal liver enzymes * hemoglobin a1c \> 6.5
antibiotic treatment for infections of short term in-dwelling vascular catheters due to gram positive bacteria

Conditions: Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia

Summary: this study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)


Eligibility criteria:
inclusion criteria: * patients with a central indwelling catheter with signs and symptoms of infection exclusion criteria: * patients with tunneled catheter which cannot be removed. * patients with evidence of endovascular infection including endocarditis. * patients with infection of permanent intravascular devices. * patients who have received more than 1 day of another antibiotic before enrollment. * patients with hiv and low cd4 count.
factors affecting the endodontic treatment outcome

Conditions: Apical Periodontitis; Apical Granuloma; Apical Cyst

Summary: the aim of this prospective cohort observational study is: (i) to assess the endodontic treatment outcome in a private specialist endodontic office in slovenia; (ii) to estimate the effect of various pre-, intra- and postoperative factors onto endodontic treatment outcome.


Eligibility criteria:
inclusion criteria: * patients referred to the private endodontic specialist office for endodontic treatment * written informed consent was obtained prior beginning of the treatment. exclusion criteria: * preoperative advanced periodontal disease * prior microsurgical root-end resection performed * apices of the tooth were not clearly discernible on any of periapical radiographs * endodontic treated teeth were extracted for non-endodontic reason * the patient did not attend a follow-up examination.

Keywords: root canal treatment outcome success
autologous fecal microbiota transplantation (auto-fmt) for prophylaxis of clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation

Conditions: Allogeneic Hematopoietic Stem Cell

Summary: the purpose of this study is to see if fecal microbiota transplantation (fmt) will prevent the future development of cdi. this is also known as fecal bacteriotherapy or stool transplant.

this is a randomized, open-label, controlled study designed to assess the efficacy of autologous fecal microbiota transplantation (auto-fmt) for prevention of clostridium difficile infection (cdi) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-hsct). patients will be enrolled prior to allo-hsct; feces will be collected and stored from all participating subjects prior to the initiation of conditioning regimens, analyzed by deep 16s rrna gene sequencing, and tested by assay for intestinal pathogens including clostridium difficile. later in the course of transplantation, following engraftment (defined as the first day of three consecutive days, that the absolute blood neutrophil count is at above f 500 mm3), subjects will undergo fecal testing for presence of bacteroidetes by 16s pcr. subjects will be eligible for study if they have a microbiologically diverse pre-transplant colonic microbiota, and if the post-engraftment specimen contains bacteroidetes at a prevalence equal to or below (0.1%)

Eligibility criteria:
inclusion criteria: * planned to undergo allo-hsct * age ≥ 18 years exclusion criteria: * as determined by the study investigators or consenting professionals, prolonged antibiotic treatment, as prevention or suppression of an ongoing infection, where treatment involves gut-perturbing antianaerobic antibiotics * has severe colitis of any etiology or a history of inflammatory bowel disease (ibd).

Keywords: recipients transplantation
nwp09 in children with attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with adhd


Eligibility criteria:
inclusion criteria: * children aged 6 to 12 years with adhd who require pharmacologic treatment for this condition exclusion criteria: * other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of adhd

Keywords: adhd methylphenidate extended-release
clinical use of magnetic resonance perfusion imaging to qualitatively assess adequate distal perfusion after endovascular revascularization in critical limb ischemia

Conditions: Lower Limb; Ischemia; Perfusion

Summary: this study evaluates the clinical effectiveness of magnetic resonance(mr) perfusion imaging to qualitatively assess adequate distal perfusion after endovascular revascularization in critical limb ischemia


Eligibility criteria:
inclusion criteria: * age 20 and above * critical limb ischemia with ulcer * ankle brachial index(abi) ≤ 0.9 or toe brachial index (tbi) ≤ 0.5 or transcutaneous oxygen pressure (tcpo2) ≤ 40mmhg * ≥ 70 percentage of stenosis of infrapopliteal artery on lower extremity computed tomography angiography or lower extremity doppler * subject understands protocol and provides written, informed consent exclusion criteria: * post-traumatic critical limb ischemia * neurogenic limb ischemia * life expectancy ≤ 2 years

Keywords: magnetic resonance perfusion imaging distal perfusion critical limb ischemia endovascular revascularization
usefulness of nesa microcurrents in the treatment of children with autism spectrum disorders

Conditions: Autism Spectrum Disorder

Summary: the term or definition of autism spectrum disorder (asd) defines a pervasive neurodevelopmental disorder in which deficits in communication and social interaction, altered sensorimotor behaviours, repetitive, restricted and stereotyped interests and activities are observed. one of the disorders most frequently associated with asd, and which most affects the quality of life of the child and his or her family, is sleep disorders; it is estimated that between 50 and 80 percent of children with asd present this alteration and generally continue to suffer from it in adolescence and adulthood; it has also been observed that there is a correlation between sleep problems and an increase in aggressive behaviour, social and emotional deficits and deficits in activities of daily living, which severely affects the child and his or her close family environment; they become emotionally destabilised in a notorious way, and this has a negative impact on their work and productive environment. the microcurrents generated by the non-invasive neuromodulation device introduce, by means of a non-invasive technique (surface electrodes), electrical energy to normalise the nervous stimulus. this makes it an excellent complementary treatment to the activity of rehabilitation treatment. its effects are achieved by establishing several input nerve pathways corresponding to the body's dermis, through which the signals are intellectualised in time-space. these signals are the basis for achieving normalisation of the nerve impulse by means of microcurrents.

the main objective will be to test the influence of surface neuromodulation applied nesa on sleep disturbances in children with autism spectrum disorders and how this is related to disruptive behaviours and quality of life in the family environment. it is estimated to take 8 months from the design, management and development of the project, and does not have sources of funding.

Eligibility criteria:
inclusion criteria: * children with a diagnosis of autistic spectrum disorder, attending school in the city of san juan de dios in las palmas de gran canaria. * children with symptoms related to sleep disturbances. * children who present episodes of disruptive behaviour. * children who may present sensory alterations or cognitive deficits. * children whose parents sign the informed consent form. exclusion criteria: * present some of the contraindications for treatment with nesa xsignal®: pacemakers, internal haemorrhages, not applying electrodes on skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or phobia of electricity. * if parents do not sign the informed consent form. * presence of uncontrolled convulsions.

Keywords: physical therapy modality sleep disorder quality of life
cellular, molecular and clinical determinants of bone strength in in vivo and human models of gh excess.

Conditions: Acromegaly

Summary: prospective observational clinical, molecular, translational study aimed at identifying the main determinants and predictive factors of fragility fracture risck in acromegaly patients


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of acromegaly * availability to carry out outpatient checks * ability to provide informed consent exclusion criteria: * pregnancy * use of glucocorticoids (except those in use for replacement therapy) * alcohol abuse * exacerbation of chronic disease * serious comorbidities (renal or hepatic failure, heart attack, stroke) * terminally ill, prolonged immobilization (\>1 week) * clinically evident fracture within the previous six months * any other cause of secondary osteoporosis within the last five years * any prolonged treatment with drugs with documented influence on bone metabolism during the previous 12 months, including treatment with antiresorptive or anabolic compounds for osteoporosis.
sensorineural hearing loss imprint

Conditions: Sensorineural Hearing Loss

Summary: this study will investigate the consequences of sensorineural hearing loss on manual dexterity and coordination skills in children.


Eligibility criteria:
inclusion criteria: * both genders with a clinical diagnosis of severe to profound snhl only. their ages were between ten to sixteen years, able to understand simple instructions by sign language, able to use both upper and lower limbs, walk and practice daily living activities independently. exclusion criteria: * children with cochlear implantation, any cognitive, physical, visual, or neurological conditions (other than snhi and vestibular impairment), history of previous upper, lower limbs, trunk deformity or surgery. all of these cases were confirmed by medical records and examined by a physical therapist, pediatrician, and audiologist
characterization of the changes in the signalling pathways during spinal cord injury-induced skeletal muscle atrophy

Conditions: Spinal Cord Injuries; Muscle Atrophy

Summary: atrogin-1 and muscle ring finger-1 are skeletal muscle specific genes, with ubiquitin ligase activities, that are upregulated during muscle atrophy in mice. the akt/gsk3 and akt/mtor pathways are involved in muscle hypertrophy in mice. recent studies by the investigators team and others have demonstrated the implication of these signalling pathways in the control of muscle mass in humans. however no study has yet investigated the involvement of these systems in the early stages of spinal cord injury induced human skeletal muscle atrophy. the investigators propose to investigate the level of expression of the different components of the ubiquitin-proteasome system together with the level of expression and activity of the akt/mtor and akt/gsk3 signalling pathways after sci in humans during the first months following the injury. a second aim of this project is to assess if a novel apparatus of electrical stimulation which generate movements by closed-loop electrical muscle stimulation may improve strength and muscle mass in these patients. the patients will be recruited jointly at the clinique romande de réadaptation (crr) in sion and the swiss paraplegic centre in nottwil. they will be randomly divided into two groups, a first group of patients will undergo a conventional treatment of rehabilitation while a second set of patients will be treated using a brand new system of electro-stimulation called motionmaker tm. biopsies will be obtained in the first weeks after admission; two other biopsies will be taken respectively 3 and 6 months post-lesion. our results will provide an increased understanding of the molecular mechanisms contributing to skeletal muscle atrophy during the early stages following sci and a characterization of the impact of endurance training in the no more voluntary innervated muscle. moreover this study will also investigate the potential improvement in the rehabilitation process by using a new system of electro-stimulation.

measures: for each group, the muscle biopsies will be divided into 3 samples which will be used for a) real-time pcr to quantify the gene expression of the different components of the ubiquitin-proteasome system (atrogin-1, murf1, nedd4, ubb and psma) b) western blotting, using anti-phospho-site specific antibodies to quantify the activities of the akt/gsk3 and akt/mtor pathways and of their downstream regulators of protein synthesis, eif2b, p70s6k and phas-1/4e-bp1and c) fiber type analysis to quantify the variation in mhc expression.

Eligibility criteria:
inclusion criteria: * acute, motor complete sci * lesion level c5-t12 exclusion criteria: * diabetes type i * pregnancy * oral anti-coagulation * osteosyntheses of the femur * hepatitis b,c or d * hiv

Keywords: functional electrical stimulation signalling pathways
dialectical behavior therapy for adolescents with fetal alcohol spectrum disorders feasibility trial

Conditions: Fetal Alcohol Spectrum Disorder

Summary: the purpose of this study is to test the feasibility of dialectical behavior therapy for adolescents (dbt-a) with fetal alcohol spectrum disorders (fasd). in partnership with a community mental health practice, genesee valley psychology (gvp), two cohorts of five adolescents with fasd and their caregivers will participate in an already existing comprehensive dbt-a program (including individual therapy, group skills training, and 24/7 phone coaching). this program has been adapted for neurodivergent teens, including the development of trainings for mental health clinicians on fasd. the aim of the current study is to assess the acceptability of dbt-a from the perspective of teens, caregivers, and clinicians. additionally, barriers and facilitators of implementing dbt-a with teens with fasd, as well as the feasibility of the research protocol will be assessed to inform later larger-scale trials.


Eligibility criteria:
inclusion criteria: * inclusion criteria: for adolescents: * ages 14-17 years * have a diagnosis of fasd under any diagnostic criteria * residing in the state of new york * willing and able to attend group sessions virtually * have one of the following: 1. a diagnosis of disruptive mood dysregulation disorder, borderline personality disorder, or multiple other serious mental health diagnoses 2. a history of multiple psychiatric hospitalizations and/or recurring presentation at psychiatric emergency rooms 3. a score of 7+ on the mclean screening instrument (msi; instrument attached and included in eligibility screen) * have functional deficits in three of five problem areas: 1. emotional dysregulation 2. impulsivity (including avoidance) 3. interpersonal challenges 4. teenager and family challenges 5. reduced awareness and focus * access to the internet and device with zoom capabilities for caregivers: * parent or legal guardian of an adolescent (ages 14-17 years) with an fasd diagnosis * residing in the state of new york * willing and able to attend group sessions virtually * access to the internet and device with zoom capabilities for clinicians: * employee of gvp * administered dbt-a to teens with fasd as part of this study exclusion criteria: * • adolescent, caregiver, or clinician has insufficient proficiency in english * primary psychotic disorder * ongoing substance/drug dependence or eating disorder at such a level that would impede engagement with dbt modalities (i.e. if an individual requires detoxification or hospitalization for stabilization) * adolescent or caregiver has a moderate to severe intellectual disability (iq \< 51)
evaluate the efficacy and safety of d-2570 in participants with moderate-to-severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: this is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .


Eligibility criteria:
inclusion criteria: 1. subject voluntarily takes part in the study after being fully informed,signs a written icf, and agrees to follow procedures specified in the study protocol; 2. plaque psoriasis assessed by the investigator as suitable for systemic treatment and stable (defined as stable as no significant outbreak of morphological change or disease activity assessed by the investigator) for at least 6 months prior to signing informed consent; 3. during the screening period and before taking the investigational drug for the first time, psoriatic surface area (bsa) ≥10%, pga score ≥ 3, pasi score ≥ 12; 4. hematology, blood chemistry and urinalysis examination were basically normal. exclusion criteria: 1. erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, reverse psoriasis, drug-induced psoriasis; 2. have other skin lesions that affect the evaluation of treatment outcomes, such as eczema; 3. history of herpes zoster/herpes simplex, or presence of herpes zoster/herpes simplex infection during the screening period; 4. have a history of tuberculosis, or active tuberculosis, or latent tuberculosis, or suspected clinical manifestations of tuberculosis infection; 5. other conditions that the investigator considers inappropriate for participation in the study.